Dunlop A. Sinclair 4
4 · Apellis Pharmaceuticals, Inc. · Filed Apr 15, 2024
Insider Transaction Report
Form 4
Dunlop A. Sinclair
Director
Transactions
- Exercise/Conversion
Common Stock
2024-04-12$13.19/sh+1,500$19,785→ 133,518 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-04-12−1,500→ 5,500 totalExercise: $13.19Exp: 2028-12-31→ Common Stock (1,500 underlying)
Holdings
- 31,855(indirect: Indirect Owner (Masa))
Common Stock
- 173,998(indirect: Indirect Owner (Epidarex))
Common Stock
Footnotes (3)
- [F1]The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
- [F2]The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.
- [F3]This option was granted on January 1, 2019 and fully vested.